Antios Therapeutics Inc. followed up its $96 million series B financing in April with another $75 million series B-1 round that reflects faith in the potential of lead candidate ATI-2173, bound for phase IIb investigation as the backbone of a once-daily, curative regimen in chronic hepatitis B virus (HBV) infection.